nach oben

Journal of Nanoparticle Research

Erschienen in:

01.09.2012 | Review

Characterization of nanoparticle-based contrast agents for molecular magnetic resonance imaging

verfasst von: Liang Shan, Arvind Chopra, Kam Leung, William C. Eckelman, Anne E. Menkens

Erschienen in: Journal of Nanoparticle Research | Ausgabe 9/2012

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

The development of molecular imaging agents is currently undergoing a dramatic expansion. As of October 2011, ~4,800 newly developed agents have been synthesized and characterized in vitro and in animal models of human disease. Despite this rapid progress, the transfer of these agents to clinical practice is rather slow. To address this issue, the National Institutes of Health launched the Molecular Imaging and Contrast Agents Database (MICAD) in 2005 to provide freely accessible online information regarding molecular imaging probes and contrast agents for the imaging community. While compiling information regarding imaging agents published in peer-reviewed journals, the MICAD editors have observed that some important information regarding the characterization of a contrast agent is not consistently reported. This makes it difficult for investigators to evaluate and meta-analyze data generated from different studies of imaging agents, especially for the agents based on nanoparticles. This article is intended to serve as a guideline for new investigators for the characterization of preclinical studies performed with nanoparticle-based MRI contrast agents. The common characterization parameters are summarized into seven categories: contrast agent designation, physicochemical properties, magnetic properties, in vitro studies, animal studies, MRI studies, and toxicity. Although no single set of parameters is suitable to define the properties of the various types of contrast agents, it is essential to ensure that these agents meet certain quality control parameters at the preclinical stage, so that they can be used without delay for clinical studies.

Vorheriger Artikel Nanotechnology research among some leading OIC member states

Nächster Artikel Synthesis of nanoparticles with frog foam nest proteins

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30:1259–1267CrossRef

Alford R, Ogawa M, Choyke PL, Kobayashi H (2009) Molecular probes for the in vivo imaging of cancer. Mol BioSyst 5:1279–1291CrossRef

Artemov D, Bhujwalla ZM, Bulte JW (2004) Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol 5:485–494CrossRef

Benet LZ (2010) Clearance (nee Rowland) concepts: a downdate and an update. J Pharmacokinet Pharmacodyn 37:529–539CrossRef

Blamire AM (2008) The technology of MRI—the next 10 years? Br J Radiol 81:601–617CrossRef

Brown SC, Palazuelos M, Sharma P, Powers KW, Roberts SM, Grobmyer SR, Moudgil BM (2010) Nanoparticle characterization for cancer nanotechnology and other biological applications. Methods Mol Biol 624:39–65CrossRef

Bulte JW (2009) In vivo MRI cell tracking: clinical studies. AJR Am J Roentgenol 193:314–325CrossRef

Cheng KT, Menkens A, Bryant S, Sullivan DC (2007) NIH MICAD initiative and guest author program opportunities. J Nucl Med 48:19NCrossRef

Cheng Z, Thorek DL, Tsourkas A (2010) Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl 49:346–350CrossRef

Chopra A, Shan L, Eckelman WC, Leung K, Mankens AE (2011) Important parameters to consider for the characterization of PET and SPECT imaging probes. Nucl Med Biol 38:1079–1084CrossRef

Chopra A, Shan L, Eckelman WC, Leung K, Latterner M, Bryant S, Menkens A (2012) Molecular imaging and contrast agent database (MICAD): evolution and progress. Mol Imaging Biol 14:4–13CrossRef

Cipolla L, Gregori M, So PW (2011) Glycans in magnetic resonance imaging: determinants of relaxivity to smart agents, and potential applications in biomedicine. Curr Med Chem 18:1002–1018CrossRef

Corsi DM, Platas-Iglesias C, Van Bekkum H, Peters JA (2001) Determination of paramagnetic lanthanide(III) concentrations from bulk magnetic susceptibility shifts in NMR spectra. Magn Reson Chem 39:723–726CrossRef

de la Fuente JM, Grazu V (2012) Nanotechnology: inorganic nanoparticles vs organic nanoparticles, vol 4. Elsevier, Amsterdam

Debbage P, Jaschke W (2008) Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol 130:845–875CrossRef

Delikatny EJ, Poptani H (2005) MR techniques for in vivo molecular and cellular imaging. Radiol Clin North Am 43:205–220CrossRef

Di Marco M, Guilbert I, Port M, Robic C, Couvreur P, Dubernet C (2007a) Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm 331:197–203CrossRef

Di Marco M, Sadun C, Port M, Guilbert I, Couvreur P, Dubernet C (2007b) Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine 2:609–622

Eckelman WC, Kilbourn MR, Joyal JL, Labiris R, Valliant JF (2007) Justifying the number of animals for each experiment. Nucl Med Biol 34:229–232CrossRef

Eckelman WC, Kilbourn MR, Mathis CA (2009) Specific to nonspecific binding in radiopharmaceutical studies: it’s not so simple as it seems! Nucl Med Biol 36:235–237CrossRef

Fadeel B, Garcia-Bennett AE (2010) Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 62:362–374CrossRef

Fox GB, Chin CL, Luo F, Day M, Cox BF (2009) Translational neuroimaging of the CNS: novel pathways to drug development. Mol Interv 9:302–313CrossRef

Gaumet M, Vargas A, Gurny R, Delie F (2008) Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69:1–9CrossRef

Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE (2007) Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2:249–255CrossRef

Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–4021CrossRef

Haun JB, Yoon TJ, Lee H, Weissleder R (2010) Magnetic nanoparticle biosensors. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:291–304CrossRef

Hellman RN (2011) Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 31:310–316CrossRef

Hermann P, Kotek J, Kubicek V, Lukes I (2008) Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Trans 21:3027–3047CrossRef

Karmali PP, Simberg D (2011) Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 8:343–357CrossRef

Koh TS, Bisdas S, Koh DM, Thng CH (2011) Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI. J Magn Reson Imaging 34:1262–1276CrossRef

Koole R, van Schooneveld MM, Hilhorst J, Castermans K, Cormode DP, Strijkers GJ, Donega CD, Vanmaekelbergh D, Griffioen AW, Nicolay K, Fayad ZA, Meijerink A, Mulder WJM (2008) Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem 19:2471–2479CrossRef

Langley J, Liu W, Jordan EK, Frank JA, Zhao Q (2011) Quantification of SPIO nanoparticles in vivo using the finite perturber method. Magn Reson Med 65:1461–1469CrossRef

Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN (2008) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 108:2064–2110CrossRef

Leung K, Chopra A, Shan L, Eckelman WC, Menkens A (2012) Essential parameters to consider for the characterization of optical imaging probes. Nanomed 7:1101–1107CrossRef

Lodhia J, Mandarano G, Ferris N, Eu P, Cowell S (2010) Development and use of iron oxide nanoparticles (Part 1): synthesis of iron oxide nanoparticles for MRI. Biomed Imaging Interv J 6:e12CrossRef

Lowe MP (2004) Activated MR contrast agents. Curr Pharm Biotechnol 5:519–528CrossRef

Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, Maecke HR (2005) Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 46:823–830

Makowski MR, Wiethoff AJ, Jansen CH, Botnar RM (2009) Molecular imaging with targeted contrast agents. Top Magn Reson Imaging 20:247–259CrossRef

Mankoff DA, O’Sullivan F, Barlow WE, Krohn KA (2007) Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol 14:398–405CrossRef

Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545–580CrossRef

Morcos SK (2008) Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 66:175–179CrossRef

Pakzad F, Ell PJ, Carrio I (2005) Molecular imaging in animal models of disease—every little detail counts! Eur J Nucl Med Mol Imaging 32:899–900CrossRef

Ptak K, Farrell D, Panaro NJ, Grodzinski P, Barker AD (2010) The NCI alliance for nanotechnology in cancer: achievement and path forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:450–460CrossRef

Rosenblum LT, Kosaka N, Mitsunaga M, Choyke PL, Kobayashi H (2010) In vivo molecular imaging using nanomaterials: general in vivo characteristics of nano-sized reagents and applications for cancer diagnosis. Mol Membr Biol 27:274–285CrossRef

Sayes CM, Warheit DB (2009) Characterization of nanomaterials for toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:660–670CrossRef

Schladt TD, Schneider K, Schild H, Tremel W (2011) Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment. Dalton Trans 40:6315–6343CrossRef

Schrand AM, Rahman MF, Hussain SM, Schlager JJ, Smith DA, Syed AF (2010) Metal-based nanoparticles and their toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:544–568CrossRef

Shah B, Anderson SW, Scalera J, Jara H, Soto JA (2011) Quantitative MR imaging: physical principles and sequence design in abdominal imaging. Radiographics 31:867–880CrossRef

Shan L, Wang S, Sridhar R, Bhujwalla ZM, Wang PC (2007) Dual probe with fluorescent and magnetic properties for imaging solid tumor xenografts. Mol Imaging 6:85–95

Sherry AD, Caravan P, Lenkinski RE (2009) Primer on gadolinium chemistry. J Magn Reson Imaging 30:1240–1248CrossRef

Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M (2009) Preparation and in vivo imaging of PEG-poly(l-lysine)-based polymeric micelle MRI contrast agents. J Control Release 136:14–20CrossRef

Shiraishi K, Kawano K, Maitani Y, Yokoyama M (2010) Polyion complex micelle MRI contrast agents from poly(ethylene glycol)-b-poly(l-lysine) block copolymers having Gd-DOTA; preparations and their control of T(1)-relaxivities and blood circulation characteristics. J Control Release 148:160–167CrossRef

Tao L, Hu W, Liu Y, Huang G, Sumer BD, Gao J (2011) Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp Biol Med (Maywood) 236:20–29CrossRef

Tei L, Mazooz G, Shellef Y, Avni R, Vandoorne K, Barge A, Kalchenko V, Dewhirst MW, Chaabane L, Miragoli L, Longo D, Neeman M, Aime S (2010) Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity. Contrast Media Mol Imaging 5:213–222CrossRef

Tinkle SS (2010) Maximizing safe design of engineered nanomaterials: the NIH and NIEHS research perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:88–98CrossRef

Weissleder R (2006) Molecular imaging in cancer. Science 312:1168–1171CrossRef

Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 152:167–173

Titel: Characterization of nanoparticle-based contrast agents for molecular magnetic resonance imaging
verfasst von: Liang Shan
Arvind Chopra
Kam Leung
William C. Eckelman
Anne E. Menkens
Publikationsdatum: 01.09.2012
Verlag: Springer Netherlands
Erschienen in: Journal of Nanoparticle Research / Ausgabe 9/2012
Print ISSN: 1388-0764
Elektronische ISSN: 1572-896X
DOI: https://doi.org/10.1007/s11051-012-1122-z

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht

Springer Professional

Abstract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Weitere Artikel der Ausgabe 9/2012

Preparation of hydrosol suspensions of elemental and core–shell nanoparticles by co-deposition with water vapour from the gas-phase in ultra-high vacuum conditions

Development of risk-based nanomaterial groups for occupational exposure control

Photo-induced tunable local oxidation and fragmentation in Pt ultra-nanoclusters functionalized GaN nanotubes

Decoration of ultrafine platinum-ruthenium particles on functionalized graphene sheets in supercritical fluid and their electrocatalytic property

Magnetic properties of electron-doped La0.23Ca0.77MnO3 nanoparticles

Characterization of carbon nano-onions for heavy metal ion remediation

Premium Partner

Marktübersichten